C A Penning

1.1k total citations
17 papers, 918 citations indexed

About

C A Penning is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, C A Penning has authored 17 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 5 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in C A Penning's work include Systemic Sclerosis and Related Diseases (4 papers), Inflammatory Myopathies and Dermatomyositis (3 papers) and PARP inhibition in cancer therapy (3 papers). C A Penning is often cited by papers focused on Systemic Sclerosis and Related Diseases (4 papers), Inflammatory Myopathies and Dermatomyositis (3 papers) and PARP inhibition in cancer therapy (3 papers). C A Penning collaborates with scholars based in United States, United Kingdom and France. C A Penning's co-authors include Eng M. Tan, Georg Reimer, M A Lischwe, Virginia Steen, K. Michael Pollard, H. Busch, Robert Ochs, Thomas A. Medsger, Hisashi Yamanaka and Dennis A. Carson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

C A Penning

17 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C A Penning United States	13	436	250	226	192	163	17	918
Ronald W. Oxenhandler United States	15	774 1.8×	191 0.8×	160 0.7×	109 0.6×	124 0.8×	24	1.2k
Haruhiko Imai Japan	14	387 0.9×	105 0.4×	223 1.0×	152 0.8×	266 1.6×	28	919
H Yamada Japan	16	167 0.4×	96 0.4×	277 1.2×	101 0.5×	61 0.4×	26	737
B. M. Czarnetzki Germany	16	360 0.8×	319 1.3×	468 2.1×	64 0.3×	55 0.3×	49	1.1k
Asahi Ito Japan	20	543 1.2×	382 1.5×	556 2.5×	170 0.9×	177 1.1×	68	1.4k
Daniel C. Zedek United States	16	259 0.6×	274 1.1×	130 0.6×	114 0.6×	117 0.7×	41	762
Yuji Kozuka Japan	15	231 0.5×	259 1.0×	113 0.5×	82 0.4×	130 0.8×	48	791
Paul Hobby United Kingdom	16	218 0.5×	344 1.4×	954 4.2×	65 0.3×	97 0.6×	24	1.3k
G. E. Moore United States	18	336 0.8×	258 1.0×	223 1.0×	122 0.6×	82 0.5×	51	882
Laura K. Fogli United States	8	317 0.7×	385 1.5×	157 0.7×	83 0.4×	54 0.3×	17	754

Countries citing papers authored by C A Penning

Since Specialization

Citations

This map shows the geographic impact of C A Penning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C A Penning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C A Penning more than expected).

Fields of papers citing papers by C A Penning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C A Penning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C A Penning. The network helps show where C A Penning may publish in the future.

Co-authorship network of co-authors of C A Penning

This figure shows the co-authorship network connecting the top 25 collaborators of C A Penning. A scholar is included among the top collaborators of C A Penning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C A Penning. C A Penning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Kristeleit, Rebecca, Ірина Давиденко, Vadim Shirinkin, et al.. (2017). A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecologic Oncology. 146(3). 484–490. 78 indexed citations

Bissett, Donald, Kenneth J. O’Byrne, Joachim von Pawel, et al.. (2005). Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 23(4). 842–849. 7 indexed citations

Hsyu, Poe‐Hirr, Yazdi K. Pithavala, Merril Gersten, C A Penning, & Bradley M. Kerr. (2002). Pharmacokinetics and Safety of an Antirhinoviral Agent, Ruprintrivir, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 46(2). 392–397. 32 indexed citations

Pivot, Xavier, Scott Wadler, C. Kelly, et al.. (2001). Result of two randomized trials comparing nolatrexed (Thymitaq™) versus methotrexate in patients with recurrent head and neck cancer. Annals of Oncology. 12(11). 1595–1599. 24 indexed citations

Huff, J P, Barry J. Grant, C A Penning, & Kevin F. Sullivan. (1990). Optimization of routine transformation of Escherichia coli with plasmid DNA.. PubMed. 9(5). 570–2, 574, 576. 47 indexed citations

Simonin, Frédéric, Josiane Ménissier‐de Murcia, Olivier Poch, et al.. (1990). Expression and site-directed mutagenesis of the catalytic domain of human poly(ADP-ribose)polymerase in Escherichia coli. Lysine 893 is critical for activity.. Journal of Biological Chemistry. 265(31). 19249–19256. 70 indexed citations

Yamanaka, Hisashi, et al.. (1989). Characterization of Poly(ADP-Ribose) Polymerase with Human Autoantibodies. Advances in experimental medicine and biology. 259–265. 2 indexed citations

Thibodeau, Jacques, Gérard Gradwohl, Christian Dumas, et al.. (1989). Cloning of rodent cDNA encoding the poly(ADP-ribose) polymerase catalytic domain and analysis of mRNA levels during the cell cycle. Biochemistry and Cell Biology. 67(9). 653–660. 21 indexed citations

Reimer, Georg, Virginia Steen, C A Penning, Thomas A. Medsger, & Eng M. Tan. (1988). Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis & Rheumatism. 31(4). 525–532. 163 indexed citations

10.

Yamanaka, Hisashi, et al.. (1988). Characterization of human poly(ADP-ribose) polymerase with autoantibodies.. Journal of Biological Chemistry. 263(8). 3879–3883. 97 indexed citations

11.

Penning, C A, Hisashi Yamanaka, Dennis A. Carson, et al.. (1987). The effect of in vitro neuropeptides np on systemic lupus erythematosus sle lymphocytic mitogen responses and natural killer nk activity. Clinical research. 35(3). 566. 1 indexed citations

12.

Yamanaka, Hisashi, et al.. (1987). Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase.. Journal of Clinical Investigation. 80(3). 900–904. 49 indexed citations

13.

Reimer, Georg, K. Michael Pollard, C A Penning, et al.. (1987). Monoclonal autoantibody from a (new zealand black x new zealand white)F₁ mouse and some human scleroderma sera target an MT_r 34,000 nucleolar protein of the U3 RNP particle. Arthritis & Rheumatism. 30(7). 793–800. 234 indexed citations

14.

French, Martyn A., Gillian Harrison, C A Penning, et al.. (1985). Serum immune complexes in systemic sclerosis: relationship with precipitating nuclear antibodies.. Annals of the Rheumatic Diseases. 44(2). 89–92. 13 indexed citations

15.

French, Martyn A., Gillian Harrison, C A Penning, et al.. (1985). Serumimmunecomplexes insystemic sclerosis: relationship withprecipitating nuclear antibodies. 1 indexed citations

16.

Penning, C A, Martyn A. French, N.R. Rowell, & Pamela Hughes. (1985). Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic lupus erythematosus.. PubMed. 17(3). 125–30. 21 indexed citations

17.

Penning, C A, Julie M. Cunningham, Martyn A. French, et al.. (1984). Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic sclerosis.. PubMed. 57(3). 548–56. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact